Rawat Ekta, Sharma Suman, Vyas Shweta, Alsaidan Omar Awad, Kapoor Devesh U, Prajapati Bhupendra G
Manav Rachna University, Faridabad 121004 Haryana, India.
Department of Pharmacy, Banasthali Vidyapith, Banasthali 304022 Rajasthan, India.
Int J Pharm. 2025 Aug 20;681:125851. doi: 10.1016/j.ijpharm.2025.125851. Epub 2025 Jun 13.
Brain disorders, encompassing neurodegenerative conditions and intracranial neoplasms, present formidable obstacles in the realm of pharmacological delivery due to the existence of athe blood-brain barrier (BBB) and the restricted bioavailability of therapeutic agents. Alginate-derived nanoformulations have emerged as highly promising systems for drug delivery, offering attributes such as biocompatibility, regulated release, and improved targeting efficacies. This review investigates contemporary advancements in alginate-based nanoformulations, with a particular emphasis on their efficacy in surmounting obstacles to successful pharmacological delivery to the brain. Initially, we furnish a comprehensive overview of alginate, underscoring its pertinent properties, biomedical applications, and inherent limitations. Subsequently, the discourse progresses to strategies for nanoformulation, which encompass lipid-based, polymeric, and inorganic methodologies, with a focus on their benefits in relation to cerebral targeting. Moreover, this review entails the therapeutic potential of alginate-based nanoformulations in addressing significant neurological disorders, including Alzheimer's disease, Parkinson's disease, brain tumours, traumatic brain injury, epilepsy, and amyotrophic lateral sclerosis. By amalgamating cutting-edge nanotechnology with the distinctive properties of alginate, these formulations signify a promising pathway for the advancement of efficacious therapies aimed at brain targeting. Additionally, prospective research trajectories and challenges associated with the optimization of alginate-based nanocarriers for clinical applications are also elucidated.
脑部疾病，包括神经退行性疾病和颅内肿瘤，由于血脑屏障（BBB）的存在以及治疗药物的生物利用度受限，在药物递送领域构成了巨大障碍。藻酸盐衍生的纳米制剂已成为极具前景的药物递送系统，具有生物相容性、控释和提高靶向效果等特性。本综述研究了基于藻酸盐的纳米制剂的当代进展，特别强调了它们在克服成功向脑部进行药物递送障碍方面的功效。首先，我们全面概述了藻酸盐，强调其相关特性、生物医学应用和固有局限性。随后，论述进展到纳米制剂的策略，包括基于脂质、聚合物和无机的方法，重点是它们在脑靶向方面的优势。此外，本综述还探讨了基于藻酸盐的纳米制剂在治疗重大神经系统疾病方面的潜力，包括阿尔茨海默病、帕金森病、脑肿瘤、创伤性脑损伤、癫痫和肌萎缩侧索硬化症。通过将前沿纳米技术与藻酸盐的独特特性相结合，这些制剂为开发针对脑部靶向的有效疗法指明了一条有前景的途径。此外，还阐明了与优化基于藻酸盐的纳米载体用于临床应用相关的前瞻性研究轨迹和挑战。
